



Franklin Biolabs and Nordic Cell Therapy Group Announce Strategic Alliance to Accelerate Cell Therapy Development

Partnership integrates preclinical CRO capabilities with specialized cell therapy consulting to streamline the path from discovery to commercialization.

King of Prussia, PA, USA, and Copenhagen, Denmark — April 30, 2026 — Franklin Biolabs, a fully integrated preclinical contract research organization (CRO) advancing genetic medicine and biologics innovation, and Nordic Cell Therapy Group, a specialized platform providing scientific and strategic expertise in cell therapy development, today announced a strategic alliance designed to support developers across the full cell therapy lifecycle.

The collaboration brings together Franklin Biolabs' comprehensive capabilities, including CMC, preclinical, and bioanalytical services, with Nordic Cell Therapy Group's integrated expertise across cell therapy R&D, CMC, advanced analytics, regulatory and clinical development, and strategic guidance, grounded in extensive industry experience. Together, the organizations will offer pharma, biotech, and emerging companies a unified, end-to-end model that streamlines the path from discovery through commercialization.

“Franklin’s partnership with Nordic Cell Therapy Group offers unique access to the team’s deep expertise in cell therapy development, consulting, and advanced analytical strategies, with an emphasis in ophthalmology, including inherited retinal diseases,” said Dr. Vatsala Naageshwaran, Chief Executive Officer of Franklin Biolabs. “By aligning Franklin’s tenured experience in the cell and gene therapy space with Nordic’s specialized capabilities, we can provide clients with a cohesive and efficient development experience, ultimately helping bring transformative cell therapy treatments to patients faster.”

“By combining our capabilities across consulting, analytics, and cell therapy development with Franklin’s rich history and legacy in the genetic medicine space, originating from its time as the Gene Therapy Program at the University of Pennsylvania, we can offer clients a fully integrated model designed to bridge preclinical and manufacturing workflows, enabling developers to move forward with greater confidence and efficiency.” said Dr. Carlos Villaescusa, Co-Founder, CEO & CSO of Nordic Cell Therapy Group.

About Franklin Biolabs

Franklin Biolabs is a fully integrated preclinical CRO accelerating cell, gene, RNA, and biologics therapies from discovery to commercialization. Headquartered in Philadelphia and founded by gene therapy pioneer Dr. Jim Wilson, the company provides comprehensive services including viral vector production, analytics, immunology, molecular bioanalysis, and preclinical pharmacology and toxicology studies to biotech, pharma, and academic partners worldwide. Learn more at www.franklinbio.com.

About Nordic Cell Therapy Group

Nordic Cell Therapy Group is a specialized platform advancing the development of cell-based therapies through integrated expertise in consulting, analytics, and therapeutic development. The organization partners with innovators, biotech and pharmaceutical companies, and academic teams to accelerate the translation of regenerative medicine, combining scientific depth, development experience, and strategic insight to move therapies closer to patients. Learn more at <https://nordiccelltherapy.com>.